Author

Kimberley A. Mander

Observed names: K. Mander, Kimberley Mander, Mander, Kimberley Anne

Institutions: The University of Sydney, National Health and Medical Research Council

Observed institutions: The University of Sydney, National Health and Medical Research Council, The University of Adelaide, University of California, Davis

ORCID: 0009-0009-5777-4561

Observed ORCID: 0009-0009-5777-4561

OpenAlex ID: A5114069757

Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation

2016 · Frances Corrigan, Kimberley A. Mander, et al. · Journal of Neuroinflammation · 347

Cytokine‐mediated blood brain barrier disruption as a conduit for cancer/chemotherapy‐associated neurotoxicity and cognitive dysfunction

2016 · Hannah R. Wardill, Kimberley A. Mander, et al. · International Journal of Cancer · 184

Toll-like receptor 4 signaling: A common biological mechanism of regimen-related toxicities

2014 · Hannah R. Wardill, Ysabella Z.A. Van Sebille, et al. · Cancer Treatment Reviews · 37

Clostridium perfringens type D epsilon toxin produces a rapid and dose-dependent cytotoxic effect on cerebral microvascular endothelial cells in vitro

2019 · Kimberley A. Mander, Francisco A. Uzal, et al. · Journal of Veterinary Diagnostic Investigation · 10

Application of a revised model for coping with advanced cancer to qualitatively explore lung cancer survivors’ experiences of ongoing physical effects, novel treatments, uncertainty, and coping

2023 · Rebekah Laidsaar-Powell, Phyllis Butow, et al. · Journal of Cancer Survivorship · 9

Carrying on with life as a lung cancer survivor: a qualitative study of Australian survivors’ employment, finances, relationships, and healthcare experiences

2024 · Rebekah Laidsaar-Powell, Phyllis Butow, et al. · Translational Lung Cancer Research · 8

Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents

2014 · Kimberley Mander, Elizabeth Harford-Wright, et al. · Recent Patents on CNS Drug Discovery · 8

Integrated cellular, proteomic and metabolomic profiling of immune-related adverse events in non-small cell lung cancer

2026 · Natalie J. Smith, Bavani Gunasegaran, et al. · Frontiers in Immunology

The patient experience of pathways to lung cancer diagnosis in primary care: A mixed methods investigation of factors influencing timeliness of diagnosis

2026 · Kimberley Mander, Adeline Yap, et al. · Patient Education and Counseling

The Patient Experience of Pathways to Lung Cancer Diagnosis in Primary Care: a Mixed Methods Investigation of Factors Influencing Timeliness of Diagnosis

2026 · Kimberley Mander, Adeline Yap, et al. · SSRN Electronic Journal

The Patient Experience of Pathways to Lung Cancer Diagnosis in Primary Care: a Mixed Methods Investigation of Factors Influencing Timeliness of Diagnosis

2026 · Kimberley Mander, Adeline Yap, et al. · SSRN Electronic Journal

EP10.01-005 Australian Lung Cancer Survivors Experiences of Novel Treatments, Healthcare, and Ongoing Physical and Psychological Needs

2022 · R. Laidsaar-Powell, P. Butow, et al. · Journal of Thoracic Oncology

The cerebrovascular response to metastatic melanoma and Clostridium perfringens type D epsilon toxin

2017 · Mander, Kimberley Anne · Adelaide Research & Scholarship (AR&S) (University of Adelaide)

Works count: 13

Citation count: 603

H-index: 7

I10-index: 4